{"id":"NCT02836873","sponsor":"Theracos","briefTitle":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment","officialTitle":"A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-23","primaryCompletion":"2018-01-11","completion":"2018-01-11","firstPosted":"2016-07-19","resultsPosted":"2021-04-27","lastUpdate":"2021-06-30"},"enrollment":312,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Bexagliflozin","otherNames":["EGT0001442","EGT0001474"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bexagliflozin tablets, 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo tablets","type":"PLACEBO_COMPARATOR"}],"summary":"This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at 24 Weeks","timeFrame":"24 weeks","effectByArm":[{"arm":"Bexagliflozin 20 mg","deltaMin":-0.59,"sd":0.065},{"arm":"Placebo","deltaMin":-0.31,"sd":0.066}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0026"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","France","Japan","Spain"]},"refs":{"pmids":["38770818"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":157},"commonTop":["Hypoglycaemia","Nasopharyngitis","Polyuria","Nausea","Urinary tract infection"]}}